Evaluation of the effect of traditional Chinese medicine on the treatment of patients with COVID-19 infection

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2022
INTERVENTION: Experimental group:Jingyin Gubiao granules, twice a day, one sachet each time, orally after meals;Control group:blank control; CONDITION: COVID‐19 PRIMARY OUTCOME: COVID‐19 nucleic acid; INCLUSION CRITERIA: 1. Meet the discharge criteria for patients infected with novel coronavirus pneumonia and stay in home health isolation for 7 days; 2. Age 18‐85 years old, gender is not limited; 3. Patients voluntarily participate and sign the informed consent.
Epistemonikos ID: f30a319f65cadd86496cb541418e76cd0287d490
First added on: May 10, 2022